Meridian
Pharma & biotech signals

Signals

Every pharma-relevant, de-duplicated event surfaced so far, primary source first. Client-scoped signals are never shown here.

Showing 121–140 of 631 signals

FDA Seeks Public Feedback to Inform Regulatory Approach for Generative AI-Enabled Medical Devices

CompaniesFDA
3 sources — primary and 2 also reporting

Largest Prospective Study in General-Risk Pregnancies Strengthens Evidence for cfDNA Fetal Risk Assessment as a Primary Screen for Recessive Conditions

CompaniesBillionToOneAssetsUnity Fetal Risk ScreenDiseasescystic fibrosisspinal muscular atrophyalpha-thalassemiabeta-thalassemia
2 sources — primary and 1 also reporting

Cumulus Neuroscience Announces Publication in Scientific Reports Demonstrating the NeuLogiq® Platform Is Feasible and Usable for At-Home, Multimodal Cognitive Assessment in People Living with ALS and FTD

CompaniesCumulus NeuroscienceAssetsNeuLogiq PlatformDiseasesAmyotrophic Lateral SclerosisFrontotemporal Dementia
2 sources — primary and 1 also reporting

Charles W.M. Roberts, MD, PhD, an internationally recognized physician-scientist, named president and CEO of St. Jude Children's Research Hospital

CompaniesSt. Jude Children's Research HospitalDiseasescancersickle cell disease
2 sources — primary and 1 also reporting

Autoinjectable PCSK9 Inhibitor; Caution on CoQ10; Ohio Doc's Rape Charges

CompaniesLIB TherapeuticsBracco ImagingPhilipsAssetslerodalcibepVueJectCardiac Workstationbempedoic acidvutrisiranbaxdrostatlorundrostatDiseasesLDL cholesterol loweringperipheral artery diseasetransthyretin amyloid cardiomyopathyatrial fibrillationAlzheimer's diseasemitral valve diseaseheart failure with preserved ejection fraction